| INTRODUCTION
Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein that has been detected primarily in prostatic epithelium. 1 While PSMA is moderately expressed in benign and hyperplastic prostate tissues, its expression level has been shown to be associated with increased tumor stage. 2, 3 An increased level of PSMA expression may directly contribute to prostate cancer development because PSMA induces aneuploidy and activates AKT signaling. 4, 5 Furthermore, a mouse model study indicated that moderate PSMA expression facilitates prostate carcinogenesis. 6 Consequently, PSMA has been evaluated not only as a diagnostic marker for prostate cancer but also as a therapeutic target. PSMA-based targeted therapies include various PSMA antibodies and small molecules that act as PSMA inhibitors. 7 Recent studies using PSMA inhibitors with α-emitters have shown dramatic responses in heavily pre-treated patients with castration-resistant prostate cancer. 8, 9 Therefore, a better understanding of the molecular mechanism underlying the regulation of PMSA expression may facilitate the proper use of these novel agents in the treatment of prostate cancer.
The regulation of PSMA expression has focused on the ciselements in its promoter and enhancer. The proximal 1-Kb promoter of the FOLH1/PMSA gene can direct reporter gene expression at low levels, 10 but the prostate-specific expression of PSMA is controlled by a 331-bp DNA fragment called PSMA enhancer (PSME). 11 PSME contains many putative transcription factor binding sites, but NFATc1 is the only transcription factor that has been shown to bind to the AP-3 site in the 5′ end of PSME to facilitate PSMA expression. 12 Interestingly, PSME also contains multiple binding sites for Sox proteins, but the role of Sox proteins in the regulation of PSMA has not been demonstrated in any experimental system. PSME-mediated transcription is suppressed by androgen, 11 and Ghosh and Heston previously postulated that androgen receptor might sequester tissue-specific transcription factors such as SRY or Sox proteins to inhibit PSME-mediated transcription. 13 We previously demonstrated that Sox7 protein contains a β-catenin interaction region, which is capable of suppressing WNT signaling. 14 We also discovered that Sox7 is frequently inactivated in colorectal and prostate cancer by promoter hyper-methylation, and we hypothesized that it may act as a tumor suppressor. 14 The suppression of WNT by Sox7 has now been observed in several other cancer types, including endometrial cancer, ovarian cancer and renal cell carcinoma. [15] [16] [17] Because the down-regulation of Sox7 expression also correlated with prostate cancer progression, 18 we set to determine whether Sox7 also regulates PSMA expression, and if so, whether this regulation requires the β-catenin interaction region of Sox7 protein.
| MATERIALS AND METHODS

| Correlation analysis
We evaluated the RNA expression data for Sox7, FOLH1, and FOLHB in prostate adenocarcinoma from five studies in cBioPortal;
Broad/Cornell (n = 57), TCGA (n = 333), MSKCC (n = 216), Michigan/ Metastatic (n = 61), and SU2C/PCF Dream Team (n = 150 Table S1 .
We also conducted simple linear regression (SLR) analysis to measure the direction and strength of linear relationship between the expression of Sox7 and FOLH1 as well as Sox7 and FOLH1B. An estimate of the true slope, P-value, 95% confidence intervals and 95% prediction intervals were obtained via PROC REG in SAS.
The Broad/Cornell (Cell2013) study contains data from 16 paired samples with expression of Sox7, FOLH1, and FOLH1B in both normal and prostate adenocarcinoma from the same patient. We tested for significant differences in expression of Sox7, FOLH1, and FOLH1B
between the means of the normal group and prostate adenocarcinoma group using Repeated Measures ANOVA. The F-statistic and P-value were obtained via PROC GLM in SAS.
| Quantitative RT-PCR
Sox7 and PSMA mRNA expression were determined by real-time RT-PCR analysis as previously described using primers listed in Supplemental Table S2 . 19 Reactions were carried out in 20-µL volume using iQ SYBR green supermix (cat# 170-8882, Bio-Rad, Hercules, CA) on a Bio-Rad iCycler. Standard curves for Sox7, PSMA, and glyceraldehyde-3-phophate dehydrogenase (GAPDH) were generated, and gene expression levels of PSMA were normalized by a comparative threshold cycle method. Standard deviations were calculated based on values from the duplicates.
| Sox7 RNAi analysis
Sox7 siRNA duplexes were purchased from Sigma-Aldrich Chemical
Co. (St. Louis, MO) (SASI_Hs01_00119451& SASI_Hs02_00358850).
Gene silencing was achieved as described previously. 20 Briefly, cells were grown to 50 ∼ 60% confluence in 6-well plates, Lipofectamine reagent (cat#11668-500, Invitrogen, Grand Island, NY) was incubated with Opti-MEM reduced serum medium (cat#31985, Invitrogen) for 10 min, and a mixture of siRNA was then added. After incubation for 20 min at room temperature, the mixture (300 µL) followed by 700 µL 2.4 | Recombinant Sox7 proteins and electrophoretic mobility shift assay Sox7-Δ mutant was generated previously 14 and Sox7-NLS mutant was generated by site-directed mutagenesis (Stratagene, Cedar
Creek, TX) in CMV-Tag2B-Sox7 plasmid using mutagenesis primers listed in Supplemental Table S2 . Mutations were validated by Sanger sequencing, and wild-type or mutant Sox7 were then cloned into pENTR-3C vector. His-tagged Sox7 proteins were generated by cloning the wild-type or mutant Sox7 into pDEST17 vector using the Invitrogen Gateway system, followed by expression in BL21 E.
coli cells and purification using ProBond Purification system (Invitrogen). Sequences of synthetic oligonucleotides are listed in Supplemental Table S2 . Oligonucleotides were end-labeled with biotin using Biotin 3′ end labeling kit (Pierce Chemical, Dallas, TX).
Electrophoretic mobility shift assay (EMSA) was carried out using Lightshift Chemiluminescent EMSA kit (Pierce Chemical).
| Luciferase reporter assay
CMV- Tag2B 
| Generation of C4-2 and 22Rv1 cell line with Sox7 expression
The "Tet-on" LNCaP/C4-2 and 22RV1 cell line was generated using the Tet-On gene expression system from Clonetech (Mountain View, CA).
Flag-tagged mouse canonical Sox7, Sox7-Δ, or Sox7-NLS were cloned into pTRE2-pur vector and transfected into the "Tet-on" LNCaP or 22Rv1 cell line. Cells were selected in culture media containing puromycin. Stable clones were isolated 14 days after selection began.
The Tet-on system was leaky, and the clones isolated all had stable Sox7 expression which was not altered by doxycycline treatment. Sox7
and PSMA protein expressions were evaluated with Western blot using actin level as a loading control.
| Chromatin immunoprecipitation (ChIP) assay
Cells were cross-linked for 10 min in 1% formaldehyde at room temperature. ChIP assay was carried out using EZ-ChIP™ Chromatin
Immunoprecipitation Kit (Cat# 17-371, Millipore, Burlington, MA). Primers are listed in Supplemental Table S2 and Supplemental Team study (Supplemental Figure S1 ).
PSME is also present in the promoter of FOLH1B which encodes prostate-specific membrane antigen-like protein (PSMAL). The DNA sequence of PSME in the FOLH1B promoter differs from that in FOLH1
at five positions, two of which altered ATF/CREB and C/EBP binding sites (Supplemental Figure S2 ). Because none of these alterations occurred inside the Sox binding sites, we also evaluated the correlation of Sox7 and FOLH1B mRNA expression in these studies. In the Broad/ Cornell study, TCGA study and MSKCC study, there was significant negative linear association between the expression of Sox7 and Figure S1 ), indicating that it cannot be observed with studies containing only metastatic prostate cancer.
The Broad/Cornell (Cell2013) study contains sixteen paired samples with both normal and prostate adenocarcinoma from the same patient. We evaluated significant differences in expression of these genes between normal prostate and prostate tumors using Repeated Measures ANOVA. The true mean expression of Sox7 was significantly lower among the prostate adenocarcinoma group than the normal group (P = 0.0004). The true mean expression of FOLH1
and FOLH1B were both significantly higher among the prostate adenocarcinoma group than the normal group (P = 0.0012 and 0.0007, respectively (Supplemental Figure S3) . These results were consistent with our previous finding that the expression of Sox7 is suppressed during the oncogenic transformation of prostate epithelium. Table S3 ). A similar trend was observed in immunoblot analysis of PSMA and Sox7 protein levels ( Figure 2B ).
Interestingly, anti-Sox7 antibody detected two bands in PC-3 cells (Supplemental Figure S4) . The weakly expressed band at 42 KDa corresponded to the canonical Sox7 (isoform 1, Q9BT81-1), and the strongly expressed band at 48.5 KDa may be a splicing isoform predicted by UniProt (isoform 2, Q9BT81-2). These two proteins differ in their N-terminal end, and isoform 2 lacks the bipartite NLS (Supplemental Figure S4A) . One of our qRT-PCR primer resided in 3.3 | Sox7 interacts with PSME in vivo and negatively regulates PSME-mediated transcription PSMA expression is stimulated by an enhancer element, PSME, in prostate cells, which contains several potential binding sites for Sox proteins. 11 To determine whether Sox7 physically interacts with PSME in vivo, we carried out ChIP analysis in C4-2 cells with ectopic Sox7 expression using a ChIP-validated anti-Sox7 antibody. 25 Our data indicated that anti-Sox7 antibody preferentially precipitated the genomic region containing PSME compared to IgG control antibody ( Figure 3A) . Furthermore, this difference was not observed when we used the same antibody pairs against a genomic region on chromosome 8 (SNP28254). 26 These data indicate that Sox7 protein preferentially interacts with PSME in vivo. FIGURE 3 Sox7 interacts with PSME in vivo and negatively regulates PSME-mediated transcription. A, ChIP analysis of C4-2/Sox7 cell line with anti-Sox7 antibody or IgG control antibody at PSME or SNP28254. Quantitative real-time PCR was carried out in triplicate, and error bars represent one standard deviation. B, Schematic drawing of luciferase reporters for PSMA promoter and enhancer (PSME) activity. PSMA1k only contains a 1-Kb promoter region. PSME-PSMA1k contains both the promoter and enhancer. C, Sox7 suppresses PSME-mediated transcription. Indicated amount of CMV-Tag2B/Sox7 (Sox7) or CMV-Tag2B (V-ctrl) plasmids were transfected into LNCaP cells with 100 ng of PSME-PSMA1k luciferase reporter construct. Control reactions were carried out by transfecting 100 ng of pGL3 or PSMA1 K plasmids.
Reactions were carried out in duplicates, and error bars represent one standard deviation
We also evaluated the role of Sox7 protein in PSME-mediated transcription. The proximal 1-Kb promoter region of FOLH1/PSMA was cloned into a pGL3-basic luciferase report plasmid ( Figure 3B ), and the inclusion of this promoter region did not significantly alter luciferase activity in LNCaP cells ( Figure 3C ), consistent with previous studies. 11 The inclusion of PSME in this reporter construct enhanced luciferase activity by 250-fold ( Figure 3C ). Co-transfection of a plasmid expressing a wild-type Sox7, but not a vector control, suppressed PSME-mediated transcription in a dosedependent manner ( Figure 3C ). These data suggest that over-expression of Sox7 suppresses PSME-mediated transcription in LNCaP cells.
| Sox7 directly binds to PSME in vitro
We next generated and purified recombinant His-tagged Sox7 protein (rSox7) and tested whether Sox7 directly interacts with PSME using EMSA. The potential binding sites for Sox7 in PSME are depicted in Figure 4A . A synthetic oligonucleotide duplex was generated to contain Sox binding sites 1 through 4 ( Figure 4A , probe #1).
Recombinant Sox7 formed a complex with this duplex DNA and caused a mobility shift ( Figure 4B , lane 2). Mutations in both sites 2 and 4 from ATTGT to ATTTT (probe #2) eliminated Sox7 binding, indicating that these two sites are required for Sox7 binding ( Figure 4B , lane 4).
Probe #3 only contained a mutation in site 4 but not in site 2. Even though this probe was still capable of interacting with rSox7, we observed significant reduction in the amount of shifted complex, supporting the notion that both sites 2 and 4 are involved in Sox7
binding. The binding between Sox7 and this DNA duplex was also specific because it was disrupted by excess unlabeled probe #1 but not probe #2 ( Figure 4C ). Therefore, recombinant Sox7 directly interacts with PSME through Sox binding sites 2 and 4. 3.5 | The HMG domain of Sox7 is required for PSME binding and the regulation of PSME-mediated transcription Sox7 has several evolutionarily conserved protein sequence motifs, and we have previously identified a DxxEFDQYL motif in its C-terminus to be essential for the suppression of β-catenin mediated transcription and WNT signaling. 14 The deletion of this sequence motif in Sox7, however, did not alter the binding of recombinant Sox7
protein to PSME ( Figure 5B, lane 2) . Furthermore, ectopic expression of Sox7-Δ was still capable of inhibiting PSME-mediated transcription in a dose-dependent manner ( Figure 5C ), indicating that the β-catenin interaction motif is not required for this suppressing activity. Sox7 also contains an HMG motif with a bipartite nuclear localization sequence (NLS) and a basic cluster NLS ( Figure 5A ). We used site-directed mutagenesis to convert RKR in the bipartite NSL to GTG and RPRRK in the basic cluster NLS to AAAGK ( Figure 5A ). Mutation of these two NLS motifs in other Sox proteins results in complete exclusion of the protein from the nucleus. 27 Interestingly, our data indicated that mutation of these sites in Sox7-NLS mutant also abolished the direct binding of purified recombinant Sox7 to PSME in vitro ( Figure 5B ).
Therefore, these sites may also directly participate in PSME binding.
In addition, ectopic expression of Sox7-NLS failed to suppress PSME-mediated transcription ( Figure 5C ). Hence, mutations in the NLS regions disrupt the interaction between Sox7 and PSME and the ability of Sox7 to suppress PSME-mediated transcription.
To confirm this finding in vivo, we expressed these Sox7 mutants in a 22Rv1/Tet-on cell line. The Tet-on promoter, however, was leaky in this cell line, and we observed a constitutive level of Sox7 expression under untreated conditions ( Figure 5D ). While PSMA protein was readily detected in the 22Rv1-parental and 22Rv1/Sox7-NLS cell line, it was not observed in 22Rv1/Sox7-WT and 22Rv1/Sox7-Δ cells ( Figure 5D ). We also carried out ChIP analysis in 22Rv1/Sox7-WT and 22Rv1/Sox7-NLS cells to evaluate the interaction between wild-type/ mutant Sox7 and PSME. While enhanced interaction between Sox7-WT and PSME was observed in 22Rv1/Sox7-WT cells, it was not observed between Sox7-NLS mutant and PSME ( Figure 5E ). These data are consistent with our in vitro observations that the NLS regions are essential for Sox7 to suppress PSMA expression.
| DISCUSSION
The expression of PSMA is controlled by a cis-element PSME, which is located in the third intron of PSMA/FOLH1. PSMAL/FOHL is related to PSMA/FOLH1 through gene duplication, 28 and a PSME element is also present in the promoter of this gene. Even though these two PSME elements differ by five nucleotides, they share the same binding sites for Sox proteins, and Sox7 expression negatively correlates with both PSMA/FOLH1 and PSMAL/FOLH1B expression in several large scale prostate cancer studies. This correlation led us to evaluate whether Sox7 negatively regulates PSMA expression through PSME. Our data
FIGURE 5
The NLS region but not the β-catenin interacting motif of Sox7 is essential for the regulation of PSMA expression. A, Schematic drawing of wild-type and mutant recombinant Sox7 proteins. Areas 1 and 2 represent the bipartite nuclear localization sequence and basic cluster NLS in the HMG domain, respectively. Area 3 denotes the β-catenin interacting motif. Immunoblot analysis of these recombinant proteins is included in the bottom/right of this panel. B, EMSA analysis of wild-type and mutant recombinant Sox7 proteins with probe #1. Reaction conditions were similar to those described in Figure 4B . C, Sox7-Δ but not Sox7-NLS suppresses PSME-mediated transcription. Reaction conditions were similar to those described in Figure 4B . D, Immunoblot analysis of 22Rv1, 22Rv1/Sox7-wt, 22Rv1/Sox7-Δ, and 22Rv1/Sox7-NLS cell lines. Cell lysates were harvested and analyzed by Immunoblot for PSMA and Sox7 proteins; actin was used as loading control. E. ChIP analysis of indicated 22Rv1 cell lines with anti-Sox7 antibody or IgG control antibody at PSME locus. Quantitative real-time PCR was carried out in triplicate, and error bars represent one standard deviation indicated that Sox7 directly interacts with PSME, and is capable of suppressing PSME-mediated transcription. In addition, the direct interaction between Sox7 and PSME is mediated through Sox binding sites 2 and 4. Because these two sites are separated by 20 base pairs, that is, two B-DNA double helix turns, they should face the same direction, and it will be interesting to determine in the future whether Sox7 binds to PSME as a dimer.
We also demonstrated that the restoration of canonical, wild- Even though Sox7 negatively regulates both β-catenin and PSME- Sox7 is a tumor suppressor in prostate cancer is now further supported by TCGA prostate cancer study, which indicated that approximately 11.4% of prostate tumors contain deep deletion of Sox7.
In conclusion, we have discovered that the canonical Sox7 negatively regulates PSMA expression in prostate cancer through its interaction with PSME, and the inactivation of Sox7 in prostate tumors not only leads to aberrant WNT signaling but also increases PSMA expression to promote prostate cancer progression. 
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